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 Abstract 
The research evidence regarding the potential effects of ecstasy suggests that it may 
be neurotoxic and that its use is associated with cognitive impairment. In recent years 
evidence has emerged suggesting that cannabinoids, the active ingredients in 
cannabis, can be neuroprotective under certain conditions. Given that many ecstasy 
users also consume cannabis at the same time, the possibility emerges that these 
individuals might be less susceptible to ecstasy-related impairment. The present paper 
reanalyses the data from a number of previous studies, contrasting the performance of 
those individuals who generally consume cannabis and ecstasy at the same time with 
those who generally consume ecstasy on its own. The two ecstasy-using groups are 
compared with non-ecstasy users on a range of measures including processing speed, 
random letter generation, verbal and visuo-spatial working memory span, reasoning 
and associative learning. The two ecstasy user groups did not differ significantly from 
each other on any of the measures. Both user groups were significantly worse than 
non-ecstasy users on measures of associative learning, verbal and visuo-spatial 
working memory, and reasoning. The results suggest that consuming cannabis at the 
same time as ecstasy does not reduce the likelihood of cognitive impairment.  
 There is abundant evidence that ecstasy (MDMA) is neurotoxic, disrupting 
serotonergic systems in diverse brain regions. There is also a considerable body of 
evidence that cannabis can have neuroprotective as well as neurotoxic properties. 
Given that most ecstasy users are also cannabis users (Morgan, 2000) the question 
arises as to whether concurrent use of cannabis by ecstasy users might make them less 
susceptible to MDMA related neurotoxicity. The present paper is intended to 
investigate this issue. 
Although there is abundant evidence that MDMA is neurotoxic in a range of 
animal species, evidence of neurotoxicity in humans is less extensive and sometimes 
controversial (Curran, 2000).  A review of the neuroimaging evidence can be found in 
Reneman et al (2006). A number of studies have found evidence of neurotoxicity 
among ecstasy users. For example, using PET neuroimaging, McCann, et al (1998), 
investigated 5-HT neural damage in the brains of ecstasy users.  Regions of interest 
included the frontal cortex, pariental cortex, temporal cortex, occipital cortex and 
cingulate cortex, as well as the caudate, putamen, thalamus, mid-brain, pons, 
hypothalamus and cerebellum.   The results showed that, compared to a control group, 
ecstasy users had significantly lower densities of 5HT transporter sites in all brain 
regions.  Further, the reductions observed were correlated with the extent of ecstasy 
use.   
Reneman, et al (2002a) also assessed neural injury in ecstasy users using 
single-voxel (1H) MR spectroscopy imagining.  N-Acetylasportate (NAA)/Creatine 
(CR), NAA Choline (CHO), and Myoinositol (MI) CR ratios in ecstasy users were 
measured in grey matter in the frontal and occipital cortex and in white matter in the 
parietal cortex.  The reason for focusing on NAA was that it is contained, almost 
entirely, within neuron cell bodies as well as axons and that it serves as a marker for 
neuronal loss or dysfunction. Thus the objective of the study was to evaluate whether 
ecstasy leads to alterations in metabolite ratios in NAA\Cr and NAA\Cho.  The results 
revealed that ecstasy users exhibited a reduction in NAA/Cr and NAA/Cho ratios in 
the frontal cortex compared with a control group.  No significant differences between 
groups were found in the occipital and parietal cortex.  Furthermore, a significant 
correlation was obtained between the extent of ecstasy use and NAA/Cr and 
NAA/Cho ratios in the frontal cortex.  
While most research evidence tends to concentrate on pre-synaptic 5-HT 
neurons, Reneman, et al (2002b) investigated post-synaptic 5-HT2a receptor densities 
in the cerebral cortex of human ecstasy users using single photon emission computed 
tomography (SPECT).  Current ecstasy users had significantly lower binding ratios 
when compared to previous ecstasy users and nonusers in all brain regions studied 
(frontal, parietal, and occipital cortex).   Previous users showed significantly higher 
binding ratios in the occipital cortex when compared with nonusers. This raises the 
possibility that there may be a compensatory up-regulation of post-synaptic 5-HT2a 
receptors due to low synaptic 5-HT levels in the occipital cortex of previous ecstasy 
users. 
In light of the findings reported above, it appears that ecstasy does have the 
potential to cause neurological toxicity to the serotonergic system in humans.  This in 
turn appears to adversely affect cognitive functioning in users of this drug (Morgan, 
2000).  The question emerges as to whether those ecstasy users who use cannabis 
concurrently with ecstasy are at reduced risk of harm and are less susceptible to 
cognitive deficits. While there has been abundant evidence that cannabis may 
adversely affect cognitive functioning, in recent years it has emerged that cannabis 
may possess neuroprotective properties. 
Cannabinoids, the active ingredients in cannabis (marijuana), have been found 
to be primarily neurosuppressive, reducing neuronal activity by inhibiting voltage 
dependent calcium channels and modulating potassium channels. Chronic use of 
cannabis has been shown to suppress motor activity, reduce body temperature and 
impair cognitive processes (Sarne & Keren, 2004). With regard to the last of these 
cannabis use has been shown to adversely affect the maintenance of attention, short 
term memory and executive functions (Hall & Solowij, 1998; Pope & Yurgelun-
Todd, 1996; Pope et al 2001). Animal studies have revealed that chronic 
administration of the cannabinoid THC causes hippocampal damage and impairs 
maze learning in rats (Fehr et al, 1976; Lawston et al 2000).  
However, the anti-inflammatory and anti-oxidative properties of cannabinoids 
have also raised the possibility that they may have beneficial effects in limiting 
neurological damage (Carter et al 2004; Grundy, 2002). For example, the inhibitory 
effects of cannabinoids on the excitotoxic neurotransmitter glutamate (Drysdale & 
Platt, 2003) and their capacity to counter the oxidative damage to dopaminergic 
neurones has raised the possibility that they may be of value in the treatment of 
Parkinson’s disease (Croxford, 2003). In terms of their effects on cell survival, human 
and animal studies have revealed that cannabinoids can be either neurotoxic or 
neuroprotective (Guzman et al 2001). With regard to their neuroprotective properties, 
studies have revealed that hippocampal neurones were protected from synaptically 
mediated excitotoxity by cannabinoid agonists acting through CB1 receptors.  
Furthermore as noted above, through the inhibition of voltage dependent calcium 
channels, cannabinoid agonists have been shown to protect cortical neurones from 
glutamatergic exitotoxity (Sarne & Keren, 2004). More generally various 
cannabinoids have been found to prevent neuronal cell death in experimental forms of 
acute neuronal injury such as cerebral ischaemia and traumatic brain injury (Grundy 
2002). Indeed it has been proposed that the endogenous cannabinoid system may 
serve a neuroprotective function in the brain (Sarne & Keren, 2004). 
Contrasting with these findings cannabinoids have been shown to have 
stimulatory properties inducing increased motor activity, elevated body temperature, 
and aggressive tendencies (Sarne et al, 2005). Whether cannabinoids produce 
stimulatory or inhibitory effects may depend on their concentration, the timing of 
delivery and the cell type (Guzman et al 2001). Sarne and co-workers note that while 
regular (high) concentrations of cannabinoids induced conventional (inhibitory) 
effects, low concentrations induced stimulatory effects (Sarne et al 2005; Sarne & 
Keren 2004). 
At the neuronal level low doses of cannabinoids can elevate intracellular 
calcium levels and increase transmitter release(Sarne & Keren, 2004). Doble and co-
workers note that intracellular calcium plays a key role in mediating neuronal cell 
death (Doble, 1999; Hubert & Doble, 1998). In turn these elevated levels of calcium 
are associated with the stimulation of numerous enzymes and the production of free 
radicals that attack DNA, mitochondria and the cell membrane (Sarne & Keren, 
2004). Increased intracellular calcium also stimulates the release of glutamate and the 
activation of postsynaptic NMDA receptors, which in turn facilitates the entry of 
calcium into neighbouring cells thereby spreading the damage (Doble, 1999).  
By way of contrast at higher doses cannabinoids appear to produce beneficial 
effects reducing intracellular calcium levels and the release of glutamate thereby 
acting as a neuroprotective agent. This beneficial effect might also be facilitated 
through the action of cannibinoids on other calcium dependent mechanisms for 
example inhibiting NO synthesis and attenuating the release of pro-inflammatory 
agents (Sarne & Keren, 2004).  
Exposure to low concentrations of cannabinoids over a prolonged period of 
time is likely to result in neurotoxic effects (Rubovitch et al 2004; Sarne & Keren, 
2004; Sarne et al 2005) while an acute administration at high concentrations at the 
time of trauma may be neuroprotective. For at least a week following the ingestion of 
cannabis, THC and its metabolites are stored in small quantities in body fat, leaking 
out into the circulatory system. Thus regular cannabis users may have continuous 
exposure to low concentrations of cannabinoids giving rise to neurotoxic effects.  
The implications of these dual effects for ecstasy/cannabis users are 
potentially complex. Sarne and Keren (2004) have shown that the level of THC 
immediately following cannabis ingestion is sufficient to produce neuroprotective 
effects and thus might serve to counter the neuronal damage associated with 
administration of MDMA. On the other hand, as THC concentrations decline in the 
week following cannabis administration, cannabis-related neurotoxic effects might 
emerge. 
At a more indirect level, it is well documented that the neurotoxic effects of 
MDMA are exacerbated by increases in core body temperature (Malberg et al, 1996) 
and ambient temperature (Malberg and Seiden, 1998) such that temperature is an 
important factor in determining the extent of serotonin neurotoxicity. As cannabis 
(more specifically CB1 cannabinoid receptors) is known to decrease core body 
temperature (e.g. Azad et al, 2001; Rawls et al, 2002), then it is possible that the 
neurotoxic potential of MDMA is further attenuated in ecstasy/cannabis users. 
According to Sarne and co-workers whether this temperature reduction occurs may be 
dose dependent with small infrequent doses of cannabinoids resulting in elevated 
body temperature and larger doses having the opposite effect (Sarne & Keren, 2004; 
Sarne et al 2005). 
Individuals who usually consume ecstasy on its own would not benefit from 
the neuroprotective effects of cannabis and would therefore be more likely to sustain 
MDMA related neuronal damage. On the other hand they would not be susceptible to 
the neurotoxic effects of cannabis. In reality most ecstasy user also consume cannabis, 
if not at the same time as ecstasy then at other times. Thus what potentially 
distinguishes the two groups is susceptibility to MDMA related damage. Relative to 
individuals who use ecstasy on its own, it might be reasonable to expect that 
combined ecstasy/cannabis users would be less susceptible to neurotoxic damage and 
therefore less likely to exhibit cognitive deficits. 
Previous research from our laboratory has revealed a range of cognitive 
deficits in ecstasy users (e.g., Fisk et al 2005; Montgomery et al 2005b; Wareing et al. 
2005). However, we have not previously discriminated between individuals who 
consume ecstasy on its own and those who routinely take the drug with cannabis. 
Fortuitously, since our research commenced, we have asked ecstasy users to indicate 
whether they typically take ecstasy on its own or with other drugs. Thus it is possible 
for us to divide the ecstasy user group between those who seldom used cannabis at the 
same time as ecstasy and those who frequently used cannabis at the same time. Thus 
we have reanalysed the existing data collected by our laboratory comparing the 
performance of these two groups with each other and with a non-ecstasy user control 
group. Assuming that cannabis may exhibit neuroprotective properties when taken 
with ecstasy, it is expected that those users who generally do not consume cannabis at 
the same time as taking ecstasy will show more evidence of impairment relative to 
those who consume ecstasy and cannabis together. 
 
METHOD 
Participants. 
Participants were recruited through direct approach to university students at 
Edge Hill College of Higher Education and Liverpool John Moores University. 
Following this, additional participants were forthcoming via the “snowball technique” 
(Solowij et al, 1992). Sample sizes for each analysis may be found in Table 1. In all 
cases it is apparent that females predominate in the nonuser group, accounting for 
approximately two-thirds of the sample in each case, while in the two user groups the 
gender split is more equal. With regard to information processing speed, the data were 
originally collected by Wareing (2005); the random letter generation data were 
originally collected by Wareing et al (2002) and Fisk et al (2004); the reading span. 
data by Wareing et al (2004); the computation span data by Wareing et al (2004), Fisk 
et al (2004), and Montgomery et al (2005b); the spatial working memory data by 
Wareing et al (2005); the associative learning data from Montgomery et al (2005a); 
and the syllogistic reasoning data from Montgomery et al (2005c) and Fisk et al 
(2005). 
<insert Table 1 about here> 
Materials. 
Information Processing Speed. Two measures of processing speed were 
obtained following the procedure devised by Fisk and Warr (1996). The first involved 
a letter comparison speed task in which participants were presented with two rows of 
letters on a computer screen.  They were asked to classify these as quickly as possible 
by pressing the "/" key if the two rows were the same, and the "z" key if they were 
different. The two rows of letters were identical in half of the trials but differed (by 
one letter only) in the other half.  In each trial, the letters were randomly chosen from 
the set of consonants and the position of the non-identical letter within the string was 
randomised.  For the first 30 seconds, each presented row consisted of three letters, 
for the next 30 seconds each row contained six letters, and for the third 30 seconds 
each row consisted of nine letters.  For each level of complexity (three, six, or nine 
letters), the computer kept a record of the number of correct responses. This task was 
repeated three times. 
The pattern comparison speed task was structured in exactly the same way as 
the letter comparison task.  However, the stimulus was a matrix potentially consisting 
of a basic grid of nine cells (three across and three down).  Line segments defined the 
borders of each cell and the targets were made up of three, six, or nine such line 
segments randomly selected from the basic grid. Two patterns were displayed, one in 
the top and one in the bottom half of the screen. As in the letter task, the objective was 
to classify as many pairs as "the same" or "different" within a fixed time period.  For 
the first 30 seconds, patterns consisted of three line segments, for the next 30 seconds 
they comprised six line segments, and for the third 30 seconds they were made up of 
nine line segments.   
Reading Span involved two elements, firstly participants were required to 
process a sentence by answering a simple multiple choice comprehension question; 
and secondly they were asked to recall the final word of that sentence.  As the task 
proceeded, the number of sentences that had to be processed, while recalling the last 
word of each, gradually increased.  Once all of the sentences in a given set had been 
processed, the participant was asked to recall all of the final words in the order in 
which they occurred.  The task commenced with three trials containing just a single 
sentence, this was followed by three trials with two sentences presented 
consecutively, and then three trials with three consecutive sentences, and so on.  Span 
was defined as the maximum number of end words successfully recalled in serial 
order. This level had to be achieved in at least two of the three relevant trials and the 
corresponding multiple-choice questions had to be answered correctly. 
Computation Span.  This task is analogous to reading span, but uses arithmetic 
processing rather than sentence comprehension.  With the computation span task 
simple arithmetic problems were presented, for example, 7+3 = ?, and the individual 
attempted to solve the problem while recalling the second digit of each presented 
problem.  As with the reading span task, computation span commenced with three 
trials with one arithmetic problem and increased by one problem to two, three etc. 
Span was defined in a similar manner to reading span. 
Spatial Working Memory Task.  This task was developed by Fisk (2004) and 
is similar to Miyake et al’s (2001) spatial working memory measure. Participants 
were presented with a four-by-four matrix containing five highlighted cells on a 
computer monitor for three seconds. The task commenced with three trials with one 
matrix being displayed. On the next three trials two matrices were presented 
sequentially, and the number increased by one matrix at a time up to a maximum of 
six. In each matrix, one of the highlighted cells was filled with 00000’s and the 
participant had to remember the position of that cell while at the same time indicating 
(by pointing) whether the number of cells highlighted was greater at the top of the 
matrix or at the bottom. After all of the matrices in a particular set had been presented, 
the participant was required to indicate, on a blank grid, the position of the ‘00000’ 
marked cells in the order in which they had occurred. The task generated a span score 
corresponding to the maximum number of ‘00000’ marked cells recalled in the order 
presented. This level had to be achieved in at least two out of the three trials at a given 
level. The task is analogous to global working memory measures such as computation 
span and reading span in that it requires the concurrent processing and storage of 
information. However, it is not reliant on the phonological aspect of working 
memory. 
Associative Learning. This was assessed via a verbal paired-associates task. 
Participants were presented sequentially with the same eight word pairs (see 
Montgomery et al 2005a) on a computer screen. For example,  
  DOOR   CASE 
  YEAR   PAGE 
After each presentation, the participant was prompted with the first member of 
each pair and required to recall the second member. Eight such trials were 
administered. The order of presentation was randomised and changed for each trial. 
Measures included the number of correct responses in trial 1 (a measure of initial 
learning), forgetting, the number of trials required to learn all associations, and the 
number of perseverative errors (giving the same incorrect answer in consecutive 
trials).  
Random letter generation task. Participants were asked to speak aloud a letter 
each time they heard an auditory signal.  They were asked to avoid generating 
alphabetical sequences and repeat sequences such as AB or BBC.  They were also 
asked to try and produce each letter with the same overall frequency.  Each participant 
produced three sets of 100 letters, at the rate of one per second, one every two seconds 
and one every four seconds.  The order in which the sets were produced was 
randomised for each participant. The experimenter recorded participants’ responses. 
This task yields four separate measures for each generation rate. These are the total 
number of letters produced, the number of alphabetically ordered pairs, the number of 
times that any given letter pair is repeated, and redundancy, which is a measure of the 
extent to which each letter of the alphabet is produced equally often. Sequences 
containing relatively few letters that are repeated often, produce high redundancy. For 
each of these measures, the scores were standardised and averaged over the three 
generation rates thereby producing mean standardised scores for alphabetical 
sequences, repeat sequences, redundancy, and the total number of letters generated. 
For the first three of these a high score is associated with poor performance, for total 
number of letters a high score is indicative of efficient performance. 
Syllogistic reasoning. Syllogistic reasoning requires a participant to draw valid 
inferences from a set of premises. For Example,  
  Given that:   Some A are B,  
and 
           No B are C 
 It follows that:  Some A are not C.  
 
Johnson-Laird (1983) maintains that reasoning involves constructing mental models 
of the premises and testing conclusions against these models. Constructing a single 
model may solve some problems, others may require up to three models. The more 
complex the problem, the greater number of models required and the greater is the 
load on working memory and executive resources. The syllogisms were presented in 
abstract form as in the example set out above. Participants attempted to generate 
solutions for four one-model syllogisms, four three-model syllogisms, and four 
syllogisms for which there was no valid conclusion (NVC). The syllogisms were the 
same as those used by Fisk and Sharp (2002). Scores were based on the number of 
correct solutions, or in the case of the NVC syllogisms, a response was deemed 
correct when the participant indicated that no valid conclusions were possible. 
According to Johnson-Laird (1983), NVC syllogisms require either two or three 
mental models in order to derive the correct solution. In the present study, two of the 
NVC syllogisms were two-model and two were three-model. Therefore, in terms of 
the number of models required, three-model and NVC syllogisms were the hardest, 
and one-model the easiest. The syllogisms used in the study were presented in random 
order. The test was administered following the procedure outlined by Fisk and Sharp 
(2002). 
Procedure. 
The procedures varied across the different studies and details may be found in the 
original papers. All studies were conducted in accordance with the ethical guidelines 
of the British Psychological Society. Approval was obtained from the Ethics 
Committee of Liverpool John Moores University. With regard to distinguishing 
between the ecstasy/cannabis group and the ‘ecstasy-only’ group, in all studies 
ecstasy users were asked to indicate which drugs they used at the same time as using 
ecstasy and further to indicate the frequency of concurrent use on a four point scale: 
never, occasionally, frequently, always. Thus it was possible to identify those ecstasy 
users who said that they never or occasionally used cannabis when using ecstasy. 
These are described below as ‘ecstasy-only’ users. We were also able to identify those 
ecstasy users who indicated that they frequently or always used cannabis when using 
ecstasy. These are described as ecstasy/cannabis users. Clearly most of the former 
group, the ‘ecstasy-only’ users, do in fact consume cannabis but this is generally not 
at the same time as using ecstasy. 
Design 
Information processing speed. A mixed design was employed with type of task 
(letters versus patterns), trial (with three levels) and stimulus complexity (low, 
medium and high) within participants and group (nonusers, ‘ecstasy-only’ users, 
ecstasy/cannabis users) between participants. Dependent variables were the number of 
correct responses and the number of errors. 
Random letter generation. A between participant design was employed with 
group (nonusers, ‘ecstasy-only’ users, ecstasy/cannabis users) between participants. 
Dependent variables were the number of alphabetical and repeat sequences, 
redundancy and the number of letters produced. 
Reading span, computation span, and spatial working memory. In each case, a 
between participant design was employed with group (nonusers, ‘ecstasy only’ users, 
ecstasy/cannabis users) between participants. The dependent variables were the 
respective span scores. 
Associative learning. A between participant design was employed with group 
(nonusers, ‘ecstasy only’ users, ecstasy/cannabis users) between participants. The 
dependent variables were trials to completion, the number of correct responses on trial 
one, total number of previously learned responses subsequently forgotten, and the 
number of perseverative errors. 
Syllogistic reasoning. A mixed design was used with level of difficulty (easy 
and hard) within participants and group (nonusers, ‘ecstasy-only’ users, 
ecstasy/cannabis users) between participants.  
Post-hoc Tests. In all cases, with regard to group differences, pairwise 
comparisons were made using Tukey’s HSD test. 
 
RESULTS 
Background Variables. 
Life time ecstasy dose. Inspection of Table 2 reveals that ecstasy/cannabis 
users generally had a higher lifetime dose compared with the ecstasy/non cannabis 
users. The difference was statistically significant for the processing speed sample, 
t(50.15) = 2.08, p<.05 but not for any of the other samples
1
.  
<insert Table 2 about here> 
Age. For the samples completing the processing speed, random generation and 
learning tasks there were no significant age differences, F < 1; F(2,133) = 2.20; and 
F(2,92) = 1.36 respectively, p>.05 in all cases. Significant differences or differences 
approaching significance were obtained for the samples completing the reading, 
computation, spatial working memory span and syllogistic reasoning tasks; F(2,94) = 
3.64; F(2,186) = 3.22; F(2,76) = 2.90, p = .061; and F(2,100) = 5.44 respectively; 
p<.05 unless otherwise noted. In each of these analyses, only one pairwise 
comparison was statistically significant at p<.05: in all cases the ecstasy/cannabis 
users were significantly younger than ‘ecstasy-only’ users. 
Years of Education. Years of full time education differed significantly for the 
processing speed sample, F(2,121) = 6.80, p<.01. Pairwise comparisons revealed that 
ecstasy/cannabis users had significantly fewer years of education compared to the 
other groups, p<.01 in both cases. Significant differences were also obtained for the 
samples completing the random generation, reading span and spatial working memory 
tasks, F(2,132) = 4.24, p<.05; F(2,93) = 4.17, p<.05.; and F(2,76) = 3.42, p<.05 
respectively. In each of these three cases, only one of the pairwise comparisons was 
significant, ecstasy/cannabis users having significantly fewer years of education 
compared to nonusers, p<.05 in all cases. For those participants completing the 
computation span task, although years of education differed significantly, F(2,186) = 
3.48, p<.05, none of the pairwise comparisons were statistically significant, p>.05 in 
all cases. Furthermore, years of education did not differ significantly for those 
samples completing the learning and syllogistic reasoning tasks, F< 1 and F(2,100) = 
1.05, p>.05 respectively. 
 Intelligence. For the samples completing the processing speed, random 
generation, reading, computation, and spatial working memory span tasks, 
intelligence was measured utilising Ravens progressive matrices, sets D and E only. 
Those participants completing the learning and syllogistic reasoning tasks, undertook 
the complete Ravens test (Sets A through to E) (Raven et al, 1998). In five of the 
seven samples no significant differences between the groups were obtained
2
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those completing the processing speed task, for Ravens Set E the overall effect was 
just short of significance, F( 2,117) = 2.89, p = .059,. However, pairwise comparisons 
revealed that ecstasy/cannabis users scored significantly lower than ‘ecstasy-only’ 
users, p<.05. There was no significant group difference in relation to Set D, F < 1. For 
the sample completing the computation span task, again the overall group differences 
were non significant. F = 3.04, p = .050 for Set D, and F = 3.01, p = .052 for Set E, 
both with df = 2, 182. However, two of the pairwise comparisons were statistically 
significant. For Set D ecstasy/cannabis users scored significantly lower than nonusers, 
and for Set E ecstasy/cannabis users scored significantly lower than ‘ecstasy-only’ 
users, p< .05 in both cases. 
 
Main Results 
The number of errors on the processing speed task yielded a significant group 
effect, F(2,122) = 3.83, p<.05. The ecstasy/cannabis group made more errors 
compared to the ‘ecstasy-only’ group and compared to nonusers (Table 3). Of the 
pairwise comparisons, only the nonuser versus ecstasy/cannabis user difference was 
significant, p<.05. None of the interactions containing user group were statistically 
significant, F<1.65 in all cases. 
<insert Table 3 about here> 
In relation to the number of correct responses on the processing speed task 
there was a significant interaction between user group and type of task, F(2,122) = 
4.01, p<.05. Compared to the other two groups, ecstasy/cannabis users were generally 
faster when processing patterns but slower when processing the letter stimuli. With 
this exception, neither the main effect of user group nor any of the interactions 
containing this variable were statistically significant, F<1.08 in all cases. 
No group differences were observed on three of the random generation 
measures, specifically for alphabetic sequences and redundancy, F < 1 in both cases 
and for repeat sequences, F(2,133) = 1.93, p>.05. There was a significant group 
difference in the number of letters generated, F(2,133) = 5.88, p<.01. Inspection of 
Table 3 reveals that ecstasy/cannabis users produced significantly fewer letters 
compared to nonusers, p<.01. None of the other pairwise comparisons were 
significant. 
Although both user groups had lower reading span scores compared to 
nonusers, the difference was not statistically significant, F(2,94) = 1.07, p > .05. 
However, on the computation span measure there was a significant overall group 
difference, F(2,186) = 14.77, p<.001. Pairwise comparisons revealed that 
ecstasy/cannabis scored significantly lower than non users, p<.001 as did ‘ecstasy-
only’ users, p<.05. The two user groups did not differ significantly from each other. 
With regard to spatial working memory, a significant overall group difference 
emerged, F(2,76) = 8.86, p<.001. Pairwise comparisons revealed that both user groups 
achieved significantly lower scores compared to nonusers, p<.05 for ‘ecstasy-only’ 
users, and p<.001 for ecstasy/cannabis users. As with the computation span measure, 
the two user groups did not differ significantly from each other. 
All of the learning measures yielded significant overall group differences. For 
initial learning, perseverative responses, total forgetting, and trials to completion, F 
values were respectively, 6.90, p<.01; 5.23, p< 01; 4.77, p<.05; and 10.92, p<.001. 
Pairwise comparisons revealed that for initial learning, ecstasy/cannabis users scored 
significantly lower than non users, p<.05. For perseverative responses, ‘ecstasy-only’ 
users did significantly worse than nonusers, p<.01. In relation to forgetting 
ecstasy/cannabis users forgot more previously learned responses compared to 
nonusers, p<.05. With regard to trials to completion, both users groups did worse than 
nonusers, p<.01 in both cases. None of the other pairwise comparisons were 
statistically significant and the two users groups did not differ significantly on any of 
the learning measures. 
In relation to performance on the syllogistic reasoning task, mixed ANOVA 
with group between participants and problem difficulty (with two levels easy and 
difficult) within participants yielded a significant interaction, F(2,100) = 3.40, p<.05. 
Users performed worse than nonusers on the easy problems while on the more 
difficult problems all participants performed at little better than chance. Subsequent 
one-way ANOVAs revealed that the overall group difference was significant for the 
easy problems, F(2,100) = 9.90, p<.001 with ecstasy/cannabis users performing worse 
than nonusers, p<.01 and ecstasy-only users also performing worse than nonusers, 
p<.001. The two user groups did not differ significantly from each other. On the more 
difficult problems there was no significant group difference, F < 1. 
  
Use of other drugs.  
Inspection of Table 4 reveals that there was occasional use of cocaine and 
amphetamine by both ecstasy user groups. Non ecstasy users had used neither of these 
two drugs during the three months prior to testing. It is also worthy of note that 
ecstasy/cannabis users consumed cannabis more frequently during the previous three 
months than either of the other two groups. Cannabis use among non-ecstasy users 
was infrequent with the majority of non-ecstasy users not using cannabis during the 
three months prior to testing. In terms of the median responses, all groups indicated 
that there use of alcohol during the previous three months was frequent or very 
frequent. 
<insert Table 4 about here> 
 
DISCUSSION 
It had been predicted that ‘ecstasy-only’ users would perform worse on all of 
the measures. However, in terms of the means, it was ecstasy/cannabis users who 
were most impaired on the majority of measures. Tukey’s post hoc comparisons failed 
to reveal any significant differences between the two ecstasy user groups on any of 
the measures. Relative to non-ecstasy users, ecstasy/cannabis users were significantly 
impaired on processing speed errors, the number of letters produced in the random 
generation task, computation span, and spatial working memory. Ecstasy/cannabis 
users also performed significantly worse on the associative learning measures. 
Compared to non-ecstasy users, they exhibited poorer initial learning, forgot more 
previously learned responses, and required more trials to learn the paired associates. 
With regard to the syllogistic reasoning measure, ecstasy/cannabis users registered 
significantly fewer correct responses compared to non-ecstasy users. 
Switching the focus to the ‘ecstasy-only’ users, Tukey’s post hoc analyses 
revealed that they were significantly worse than non-ecstasy users on the computation 
span and spatial working memory measures. They also made significantly more 
perseverative responses and required more trials to learn the paired associates. In 
addition, they achieved significantly fewer correct responses on the one-model 
syllogistic reasoning problems compared to non-ecstasy users. 
It is worthy of note that for the analyses reported above, for the most part, the 
‘ecstasy-only’ group had consumed fewer ecstasy tablets in total compared to the 
ecstasy/cannabis group. This might have resulted in any beneficial effects of 
concurrent cannabis consumption being outweighed by the greater exposure to 
ecstasy. However, only in one case was the difference statistically significant. In other 
instances the difference was well short of statistical significance. Also noteworthy 
was the fact that in all of the analyses reported above, the ecstasy/cannabis group 
consumed cannabis more frequently than the ‘ecstasy-only’ group. While some 
difference might have been expected (given the manner in which the two groups are 
defined), the discrepancy is nonetheless considerable. While in most cases ‘ecstasy-
only’ users reported that they used cannabis ‘occasionally’, ecstasy/cannabis users 
indicated that their frequency of use was ‘frequently’ or ‘always’. Thus it is possible 
that concurrent cannabis use does provide protection from the effects of MDMA, but 
that the higher incidence of cannabis use among ecstasy/cannabis users produces 
neurotoxic effects, which cancel out the benefits from reduced MDMA-related 
neurotoxicity. 
However, while this possibility cannot be ignored, an alternative argument can 
be posed. Sarne and Keren (2004) have argued that cannabis is likely to produce 
neurotoxic effects when individuals are exposed to small concentrations over 
prolonged periods. Higher concentrations are associated with neuroprotective 
properties. Recent studies from our own laboratory have revealed that ecstasy users 
consume cannabis three times a week on average (e.g., Montgomery et al 2005b). 
Thus it seems probable that concentrations of THC are unlikely to decline to a level 
that has been associated with neurotoxicity. On the other hand ecstasy-only users, 
with their infrequent pattern of use, are likely to experience low concentrations that 
may give rise to neurotoxic effects.  It is perhaps unrealistic and paradoxical to 
assume that frequent use of cannabis may actually have less potential for neurotoxicty 
than occasional use but what does seem reasonable is that both frequent and 
occasional cannabis users may be subject to cannabis-related neurotoxicity. 
With regard to future research it might be desirable to balance cannabis 
consumption between the two ecstasy users groups by restricting the sample. 
However, the results of the present study suggest that at least among the population of 
ecstasy users sampled here, those individuals who do usually take cannabis 
concurrently with ecstasy also tend to consume cannabis more frequently compared 
with ‘ecstasy-only’ users. Thus even if future research were to demonstrate that 
cannabis was neuroprotective in some restricted sample of ecstasy users, this finding 
would be of limited practical importance if it proves to be the case that the present 
sample is more represenative of the typical ecstasy user. 
The present study is not the first to examine whether cannabis used in 
conjunction with another illicit drug might have neuroprotective properties. Gonzalez 
et al (2004) found that a combined methamphetamine-cannabis using group showed 
less impairment than methamphetamine-only users on a range of cognitive measures. 
Although the differences between the two groups were nonsignificant, the 
methamphetamine only users scored significantly worse than a control drug naïve 
group while the combined methemphetamine-cannabis users did not differ 
significantly from controls. While Gonzalez et al concede that their results do not 
imply that cannabis is neuroprotective, they note that cannabis did not exacerbate the 
methamphetamine related deficits. In the present study again there is little evidence to 
suggest that cannabis is neuroprotective and while concurrent cannabis use did not 
significantly exacerbate the ecstasy-related deficit it is noteworthy that 
ecstasy/cannabis users generally performed worse than ‘ecstasy-only’ users. 
A number of limitations were evident in the present paper, for example, we 
were reliant on individuals being willing and able to provide an accurate account of 
their previous drug use. Indeed in defining the two ecstasy user groups, we needed 
users to specify the typical context in which they had taken ecstasy and our 
classification is limited by the veracity and consistency of these judgements. 
Furthermore, because of limited resources, we were unable to use urine, saliva, or hair 
samples to confirm recent patterns of drug use. However, by way of mitigation, it is 
noteworthy that most of the published studies that have probed cognitive deficits 
among ecstasy users have not resorted to urine, hair, or saliva testing  (e.g., Fox et al, 
2002; Morgan, 1998; Morgan, 1999; Parrott & Lasky, 1998; Rodgers, 2000). The 
importance of not over generalising from the present findings must also be stressed. 
For example, given that word of mouth referral was used as the primary means of 
recruiting participants, our ecstasy-user groups may not be entirely representative of 
all ecstasy users, especially those who consume the drug in settings that are unlike 
those frequented by those individuals included in the present paper. It is also 
important to note that a number of participants contributed data to more than one 
study so the participant details set out in Table 1 mask a certain degree of overlap in 
the different samples. Inspection of Table 1 also reveals that in some cases the sample 
sizes within particular cells were limited thereby reducing statistical power in some of 
the analyses. 
Finally, it must be acknowledged that the present paper is the product of an 
opportunistic exercise involving reanalysing existing data reported elsewhere and 
combining the results of a number of different studies. Clearly the present findings 
need to be replicated in an appropriately designed study in which new participants are 
recruited in a carefully balanced manner so that the effects of potentially confounding 
variables are minimised.  
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Table 1 Sample Sizes for each of the Analyses 
 Nonuser Ecstasy ‘Only’ User Ecstasy/Cannabis User 
 Total Males Total Males Total Males 
Processing Speed 
 
71 23 20 10 34 17 
Random Generation 
 
58 20 25 13 53 32 
Reading Span 
 
34 12 17 9 46 24 
Computation Span 
 
95 30 34 17 60 33 
Spatial Working 
Memory 
31 12 17 8 31 16 
Associative Learning 
 
62 18 16 8 16 10 
Syllogistic Reasoning 
 
52 16 22 10 29 18 
 
Table 2 
Background Variables for each of the Analyses 
 Nonuser Ecstasy ‘Only’ User Ecstasy/Cannabis User 
 
 Mean SD Mean SD Mean SD 
 
Processing Speed:       
Ecstasy, total 
number of tablets 
consumed 
- - 292.20 268.61 516.80   515.23* 
Age 22.45 4.54 23.15 4.l1 21.82   2.35 
Years of Education 15.66 1.94 16.35 1.76 14.38      2.46** 
Ravens Set D 
(maximum 12) 
9.74 1.65 9.50 1.54 9.38  2.12 
Ravens Set E 
(maximum 12) 
6.03 2.94 7.50 2.80 5.44  3.39 
Random Generation 
(standardised scores) 
      
Ecstasy, total 
number of tablets 
consumed 
- - 405.08 446.63 525.27  622.76 
Age 22.47 4.98 24.24 5.12 22.06  3.08 
Years of Education 15.73 1.89 15.64 2.33 14.58    2.43* 
Ravens Set D 
(maximum 12) 
9.85 1.44 8.96 1.77 9.12  2.33 
Ravens Set E 
(maximum 12) 
5.84 2.96 6.72 2.94 5.43  3.42 
Reading Span       
Ecstasy, total 
number of tablets 
consumed 
- - 471.25 508.48 497.74   639.95 
Age 23.21 6.23 25.41 5.82 21.85     2.38* 
Years of Education 15.62 1.84 15.41 2.76 14.08     2.81* 
Ravens Set D 
(maximum 12) 
9.71 1.72 8.53 1.91 8.95   2.17 
Ravens Set E 
(maximum 12) 
6.10 2.99 5.94 2.90 5.17   3.33 
Computation Span       
Ecstasy, total 
number of tablets 
consumed 
- - 355.09 393.99 480.50   590.97 
Age 21.98 4.06 23.68 4.59 21.77    2.16* 
Years of Education 15.47 2.03 15.71 2.59 14.63    2.36* 
Ravens Set D 
(maximum 12) 
9.84 1.63 9.32 1.72 9.11  2.23 
Ravens Set E 
(maximum 12) 
6.13 2.84 7.18 2.67 5.61  3.25 
Spatial Working 
Memory 
      
Ecstasy, total 
number of tablets 
consumed 
- - 471.25 508.48 597.26  728.46 
Age 23.39 6.47 25.41 5.82 21.77  2.09 
Years of Education 15.66 1.88 15.41 2.76 14.05    2.98* 
Ravens Set D 
(maximum 12) 
9.63 1.69 8.53 1.91 9.07  2.16 
Ravens Set E 
(maximum 12) 
6.03 3.02 5.94 2.90 5.40  3.33 
Associative Learning       
Ecstasy, total 
number of tablets 
consumed 
- - 260.75 201.47 402.50  433.57 
Age 21.30 1.79 22.06 1.77 21.19  1.56 
Years of Education 15.37 2.12 16.00 2.53 15.44  1.15 
Ravens Total 
(maximum 60) 
48.13 5.27 50.81 3.78 48.63  5.10 
Syllogistic Reasoning, 
Correct responses 
      
Ecstasy, total 
number of tablets 
consumed 
- - 336.86 439.13 336.43  339.12 
Age 21.12 1.55 23.05 4.26 21.28      1.44** 
Years of Education 15.54 1.99 15.50 2.77 14.76  2.84 
Ravens Total 
(maximum 60) 
47.94 5.55 47.27 6.69 47.83  6.20 
 
 
Table 3 
Performance Measures on each of the Tasks for Non Ecstasy Users, ‘Ecstasy-Only’ 
Users, and Ecstasy/Cannabis Users  
 Nonuser 
 
Ecstasy ‘Only’ User Ecstasy/Cannabis User 
 Mean SD Mean SD Mean     SD 
 
Processing Speed:       
Total Errors 1.05 0.72 1.15 0.73 1.51    1.00* 
Correct Responses, 
Letters 
17.60 3.27 17.01 3.12 16.65    2.45 
Correct Responses, 
Patterns 
15.81 3.45 15.43 2.64 16.30    2.79 
Random Generation 
(standardised scores) 
          
Alphabetic 
Sequences 
-0.01 0.75 -0.03 0.54 -0.04    0.93 
Repeat Sequences -0.04 0.51 -0.18 0.44 0.16    1.07 
Redundancy -0.04 0.69 -0.07 0.77 0.12    0.84 
Number of Letters 0.18 0.44 0.09 0.42 -0.16    0.64** 
Working Memory Span       
Reading Span 3.06 1.13 2.71 0.85 2.72    1.17 
Computation Span 4.56 1.62 3.62 1.81 3.10    1.66*** 
Spatial Working 
Memory 
4.16 1.19 3.06 1.30 2.87    1.34*** 
Associative Learning       
Initial Learning 4.32 2.01 3.69 2.18 2.25    1.77** 
Perseverative 
Responses 
0.16 0.66 0.94 1.57 0.38    0.50** 
Total Forgotten 0.48 0.94 1.13 1.20 1.38    1.78* 
Trials to Completion 4.32 1.46 5.94 1.81 6.00    2.00*** 
Syllogistic Reasoning, 
Correct responses 
      
One model (easy) 4.90 1.85 2.91 1.87 3.55    2.10*** 
Two/Three model 
(difficult) 
1.75 1.61 1.32 2.01 1.34    1.88 
       
 
*** p<.001; ** p<.01; * p<.05 
 
Table 4 
Median Use of Other Drugs Among each of the Samples 
Study/Measure Nonuser Ecstasy ‘Only’ 
User 
Ecstasy/Cannabis 
User 
Processing Speed    
Alcohol 3 3 4 
Amphetamine 1 1 1 
Cannabis 1 2 4 
Cocaine 1 1.5 1 
Random 
Generation 
   
Alcohol 3 4 4 
Amphetamine 1 1 1 
Cannabis 1 2 4 
Cocaine 1 2 2 
Reading Span    
Alcohol 3 4 4 
Amphetamine 1 1 1 
Cannabis 1 2 4 
Cocaine 1 1 1 
Computation span    
Alcohol 3 4 4 
Amphetamine 1 1 1 
Cannabis 1 2 3.5 
Cocaine 1 1 1.5 
Spatial Working 
Memory 
   
Alcohol 3 4 4 
Amphetamine 1 1 1 
Cannabis 1 2 4 
Cocaine 1 1 2 
Associative 
Learning 
   
Alcohol 3 3.5 4 
Amphetamine 1 1 1 
Cannabis 1 2 3 
Cocaine 1 1.5 2 
Syllogistic 
Reasoning 
   
Alcohol 3 4 4 
Amphetamine 1 1 1 
Cannabis 1 2 3 
Cocaine 1 1 2 
 
1 = never; 2 = occasionally; 3 = frequently; 4 = always 
                                                          
1
 T values were 0.85, 0.15, -1.09, -0.62, -1.19, and 0.00 for random generation, reading, computation, 
and spatial working memory span, learning, and syllogistic reasoning respectively. 
2
 For the sample completing the random generation task, F values were 2.80 and 1.40, for sets D and E 
respectively, df= 2, 126. For the reading span sample, F(2,87) = 2.28 and F< 1 for sets D and E 
respectively. For the spatial working memory sample, F(2,74) = 1.83 and F< 1 for sets D and E 
respectively. For the associative learning and syllogistic reasoning samples completing the total Ravens 
measure, F(2,92) =1.82 and F < 1 respectively. For all of these analyses, p>.05. 
